Recent searches
    Trending searches
    BMY logo Bristol-Myers Squibb Company +
    Bristol-Myers Squibb Company
    +
    Revenue breakdown by Products & Services
    Revenue breakdown by Geography

    Bristol-Myers Squibb Company's Revenue by Segment

    In fiscal year 2024, Bristol-Myers Squibb Company's revenue by segment (products & services) are as follows:

    • Abecma: $406.00 M
    • Abraxane: $875.00 M
    • Augtyro: $38.00 M
    • Breyanzi: $747.00 M
    • Camzyos: $602.00 M
    • Eliquis: $13.33 B
    • Opdivo: $9.30 B
    • Opdualag: $928.00 M
    • Orencia: $3.68 B
    • Pomalyst/Imnovid: $3.55 B
    • Reblozyl: $1.77 B
    • Revlimid: $5.77 B
    • Sotyktu: $246.00 M
    • Sprycel: $1.29 B
    • Yervoy: $2.53 B
    • Zeposia: $566.00 M

    Learn more about Bristol-Myers Squibb Company’s Revenue by Geography

    Check out competitors to Bristol-Myers Squibb Company in a side-by-side comparison.

    Explore additional financial metrics for Bristol-Myers Squibb Company.

    Continue reading...

    The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

    In fiscal year 2022, Bristol-Myers Squibb Company's revenue by segment is as follows:

    • Abecma generated $388.00 M in revenue, representing 0.87% of its total revenue.
    • Abraxane generated $811.00 M in revenue, representing 1.83% of its total revenue.
    • Breyanzi generated $182.00 M in revenue, representing 0.41% of its total revenue.
    • Camzyos generated $24.00 M in revenue, representing 0.05% of its total revenue.
    • Eliquis generated $11.79 B in revenue, representing 26.55% of its total revenue.
    • Empliciti generated $296.00 M in revenue, representing 0.67% of its total revenue.
    • Inrebic generated $85.00 M in revenue, representing 0.19% of its total revenue.
    • Onureg generated $124.00 M in revenue, representing 0.28% of its total revenue.
    • Opdivo generated $8.25 B in revenue, representing 18.57% of its total revenue.
    • Opdualag generated $252.00 M in revenue, representing 0.57% of its total revenue.
    • Orencia generated $3.46 B in revenue, representing 7.8% of its total revenue.
    • Pomalyst/Imnovid generated $3.50 B in revenue, representing 7.87% of its total revenue.
    • Reblozyl generated $717.00 M in revenue, representing 1.61% of its total revenue.
    • Revlimid generated $9.98 B in revenue, representing 22.47% of its total revenue.
    • Sotyktu generated $8.00 M in revenue, representing 0.02% of its total revenue.
    • Sprycel generated $2.17 B in revenue, representing 4.88% of its total revenue.
    • Yervoy generated $2.13 B in revenue, representing 4.8% of its total revenue.
    • Zeposia generated $250.00 M in revenue, representing 0.56% of its total revenue.

    The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 26.55% of its total revenue.
    The smallest segment for Bristol-Myers Squibb Company is the Sotyktu, which represents 0.02% of its total revenue.

    The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

    In fiscal year 2023, Bristol-Myers Squibb Company's revenue by segment is as follows:

    • Abecma generated $472.00 M in revenue, representing 1.09% of its total revenue.
    • Abraxane generated $1.00 B in revenue, representing 2.33% of its total revenue.
    • Augtyro generated $1,000.00 in revenue, representing 0% of its total revenue.
    • Breyanzi generated $364.00 M in revenue, representing 0.84% of its total revenue.
    • Camzyos generated $231.00 M in revenue, representing 0.54% of its total revenue.
    • Eliquis generated $12.21 B in revenue, representing 28.31% of its total revenue.
    • Inrebic generated $110.00 M in revenue, representing 0.26% of its total revenue.
    • Onureg generated $168.00 M in revenue, representing 0.39% of its total revenue.
    • Opdivo generated $9.01 B in revenue, representing 20.9% of its total revenue.
    • Opdualag generated $627.00 M in revenue, representing 1.45% of its total revenue.
    • Orencia generated $3.60 B in revenue, representing 8.35% of its total revenue.
    • Pomalyst/Imnovid generated $3.44 B in revenue, representing 7.98% of its total revenue.
    • Reblozyl generated $1.01 B in revenue, representing 2.34% of its total revenue.
    • Revlimid generated $6.10 B in revenue, representing 14.14% of its total revenue.
    • Sotyktu generated $170.00 M in revenue, representing 0.39% of its total revenue.
    • Sprycel generated $1.93 B in revenue, representing 4.48% of its total revenue.
    • Yervoy generated $2.24 B in revenue, representing 5.19% of its total revenue.
    • Zeposia generated $434.00 M in revenue, representing 1.01% of its total revenue.

    The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 28.31% of its total revenue.
    The smallest segment for Bristol-Myers Squibb Company is the Augtyro, which represents 0% of its total revenue.

    The above chart shows Bristol-Myers Squibb Company's revenue percentage share by segment (products and services).

    In fiscal year 2024, Bristol-Myers Squibb Company's revenue by segment is as follows:

    • Abecma generated $406.00 M in revenue, representing 0.89% of its total revenue.
    • Abraxane generated $875.00 M in revenue, representing 1.92% of its total revenue.
    • Augtyro generated $38.00 M in revenue, representing 0.08% of its total revenue.
    • Breyanzi generated $747.00 M in revenue, representing 1.64% of its total revenue.
    • Camzyos generated $602.00 M in revenue, representing 1.32% of its total revenue.
    • Eliquis generated $13.33 B in revenue, representing 29.22% of its total revenue.
    • Opdivo generated $9.30 B in revenue, representing 20.39% of its total revenue.
    • Opdualag generated $928.00 M in revenue, representing 2.03% of its total revenue.
    • Orencia generated $3.68 B in revenue, representing 8.07% of its total revenue.
    • Pomalyst/Imnovid generated $3.55 B in revenue, representing 7.77% of its total revenue.
    • Reblozyl generated $1.77 B in revenue, representing 3.89% of its total revenue.
    • Revlimid generated $5.77 B in revenue, representing 12.65% of its total revenue.
    • Sotyktu generated $246.00 M in revenue, representing 0.54% of its total revenue.
    • Sprycel generated $1.29 B in revenue, representing 2.82% of its total revenue.
    • Yervoy generated $2.53 B in revenue, representing 5.54% of its total revenue.
    • Zeposia generated $566.00 M in revenue, representing 1.24% of its total revenue.

    The biggest segment for Bristol-Myers Squibb Company is the Eliquis, which represents 29.22% of its total revenue.
    The smallest segment for Bristol-Myers Squibb Company is the Augtyro, which represents 0.08% of its total revenue.
    Continue reading...

    Summary Table

    Products & Services (Percent Share) 2022 2023 2024
    Abecma 0.87% 1.09% 0.89%
    Abraxane 1.83% 2.33% 1.92%
    Breyanzi 0.41% 0.84% 1.64%
    Camzyos 0.05% 0.54% 1.32%
    Eliquis 26.55% 28.31% 29.22%
    Empliciti 0.67% - -
    Inrebic 0.19% 0.26% -
    Onureg 0.28% 0.39% -
    Opdivo 18.57% 20.9% 20.39%
    Opdualag 0.57% 1.45% 2.03%
    Orencia 7.8% 8.35% 8.07%
    Pomalyst/Imnovid 7.87% 7.98% 7.77%
    Reblozyl 1.61% 2.34% 3.89%
    Revlimid 22.47% 14.14% 12.65%
    Sotyktu 0.02% 0.39% 0.54%
    Sprycel 4.88% 4.48% 2.82%
    Yervoy 4.8% 5.19% 5.54%
    Zeposia 0.56% 1.01% 1.24%
    Augtyro - 0% 0.08%
    Total Revenue 100% 100% 100%

    The above chart shows the revenue trend of different segments of Bristol-Myers Squibb Company.

    In fiscal year 2024, the Eliquis generated the most revenue ($13.33 B), and the Augtyro generated the least revenue ($38.00 M).

    The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

  • Abecma revenue decreased -13.98% ($66.00 M) from $472.00 M (in 2023) to $406.00 M (in 2024).
  • Abraxane revenue decreased -12.85% ($129.00 M) from $1.00 B (in 2023) to $875.00 M (in 2024).
  • Augtyro revenue increased 3% ($37.00 M) from $1,000.00 (in 2023) to $38.00 M (in 2024).
  • Breyanzi revenue increased 105.22% ($383.00 M) from $364.00 M (in 2023) to $747.00 M (in 2024).
  • Camzyos revenue increased 160.61% ($371.00 M) from $231.00 M (in 2023) to $602.00 M (in 2024).
  • Eliquis revenue increased 9.23% ($1.13 B) from $12.21 B (in 2023) to $13.33 B (in 2024).
  • Inrebic revenue decreased -100% ($110.00 M) from $110.00 M (in 2023) to $0.00 (in 2024).
  • Onureg revenue decreased -100% ($168.00 M) from $168.00 M (in 2023) to $0.00 (in 2024).
  • Opdivo revenue increased 3.27% ($295.00 M) from $9.01 B (in 2023) to $9.30 B (in 2024).
  • Opdualag revenue increased 48.01% ($301.00 M) from $627.00 M (in 2023) to $928.00 M (in 2024).
  • Orencia revenue increased 2.25% ($81.00 M) from $3.60 B (in 2023) to $3.68 B (in 2024).
  • Pomalyst/Imnovid revenue increased 3.02% ($104.00 M) from $3.44 B (in 2023) to $3.55 B (in 2024).
  • Reblozyl revenue increased 75.89% ($765.00 M) from $1.01 B (in 2023) to $1.77 B (in 2024).
  • Revlimid revenue decreased -5.31% ($324.00 M) from $6.10 B (in 2023) to $5.77 B (in 2024).
  • Sotyktu revenue increased 44.71% ($76.00 M) from $170.00 M (in 2023) to $246.00 M (in 2024).
  • Sprycel revenue decreased -33.37% ($644.00 M) from $1.93 B (in 2023) to $1.29 B (in 2024).
  • Yervoy revenue increased 13.05% ($292.00 M) from $2.24 B (in 2023) to $2.53 B (in 2024).
  • Zeposia revenue increased 30.41% ($132.00 M) from $434.00 M (in 2023) to $566.00 M (in 2024).
    • Continue reading...

    Summary Table

    Products & Services 2022
    Value Change
    		2023
    Value Change
    		2024
    Value Change
    Abecma $388.00 M - $472.00 M
    21.65%
    		$406.00 M
    13.98%
    Abraxane $811.00 M - $1.00 B
    23.80%
    		$875.00 M
    12.85%
    Augtyro - - $1.00 M - $38.00 M
    3,700.00%
    Breyanzi $182.00 M - $364.00 M
    100.00%
    		$747.00 M
    105.22%
    Camzyos $24.00 M - $231.00 M
    862.50%
    		$602.00 M
    160.61%
    Eliquis $11.79 B - $12.21 B
    3.54%
    		$13.33 B
    9.23%
    Empliciti $296.00 M - - - - -
    Inrebic $85.00 M - $110.00 M
    29.41%
    		- -
    Onureg $124.00 M - $168.00 M
    35.48%
    		- -
    Opdivo $8.25 B - $9.01 B
    9.21%
    		$9.30 B
    3.27%
    Opdualag $252.00 M - $627.00 M
    148.81%
    		$928.00 M
    48.01%
    Orencia $3.46 B - $3.60 B
    3.95%
    		$3.68 B
    2.25%
    Pomalyst/Imnovid $3.50 B - $3.44 B
    1.60%
    		$3.55 B
    3.02%
    Reblozyl $717.00 M - $1.01 B
    40.59%
    		$1.77 B
    75.89%
    Revlimid $9.98 B - $6.10 B
    38.90%
    		$5.77 B
    5.31%
    Sotyktu $8.00 M - $170.00 M
    2,025.00%
    		$246.00 M
    44.71%
    Sprycel $2.17 B - $1.93 B
    10.85%
    		$1.29 B
    33.37%
    Yervoy $2.13 B - $2.24 B
    5.02%
    		$2.53 B
    13.05%
    Zeposia $250.00 M - $434.00 M
    73.60%
    		$566.00 M
    30.41%
    Total Revenue $44.41 B - $43.11 B
    2.93%
    		$45.63 B
    5.85%

    Related company

    Related

    Submit feedback to Bullfincher